Jordi Martínez-Quintanilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jordi Martínez-Quintanilla has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Hector G. Palmer
Vall d’Hebrón Institut d’Oncología (VHIO), Stem Cell and Cancer Laboratory, Barcelona, Spain
81 shared publications - Débora Cabot
Translational Program, Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
68 shared publications - Elena Élez
Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
57 shared publications - Irene Chicote
Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
57 shared publications - Javier Ros
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
57 shared publications - Jordi Vergés
Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
57 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S8 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Kaplan Meier survival curves for PDX models shown in figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S8 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Kaplan Meier survival curves for PDX models shown in figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
The therapeutic benefit of the combination of the first-generation BRAF inhibitor (BRAFi) encorafenib and the EGFR-blocking antibody cetuximab in second-line metastatic colorectal cancers harboring BRAFV600E mutations remains limited and short lived. In this study, we present the preclinical characterization of the next-generation BRAFi mosperafenib (RG6344/RO7276389) in colorectal cancer models. Mosperafenib was designed as an MAPK paradox breaker. As it does not trigger phosphorylated ERK overactivation in BRAF wild-type contexts, we hypothesized that it may lead to an improved safety profile while reaching higher target coverage in the clinic. In in vivo experiments conducted in BRAFi-naïve xenograft models, mosperafenib monotherapy outperformed encorafenib/cetuximab at clinically relevant doses, indicating higher activity of mosperafenib. The combination of mosperafenib and cetuximab demonstrated potent activity with tumor regression and long survival benefits in BRAFi-naïve models and in patient-derived xenograft models derived from patients who progressed to encorafenib/cetuximab therapy, supporting the activity of mosperafenib even in BRAFi-experienced patients. Additional combination studies of mosperafenib with FOLFOX resulted in tumor regression and superior activity compared with the same combination with encorafenib. Collectively, these data provide a strong preclinical rationale for the potentially transformative activity of mosperafenib as monotherapy and as a preferred backbone BRAFi for combinatorial regimen for BRAF-mutated colorectal cancer.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
The therapeutic benefit of the combination of the first-generation BRAF inhibitor (BRAFi) encorafenib and the EGFR-blocking antibody cetuximab in second-line metastatic colorectal cancers harboring BRAFV600E mutations remains limited and short lived. In this study, we present the preclinical characterization of the next-generation BRAFi mosperafenib (RG6344/RO7276389) in colorectal cancer models. Mosperafenib was designed as an MAPK paradox breaker. As it does not trigger phosphorylated ERK overactivation in BRAF wild-type contexts, we hypothesized that it may lead to an improved safety profile while reaching higher target coverage in the clinic. In in vivo experiments conducted in BRAFi-naïve xenograft models, mosperafenib monotherapy outperformed encorafenib/cetuximab at clinically relevant doses, indicating higher activity of mosperafenib. The combination of mosperafenib and cetuximab demonstrated potent activity with tumor regression and long survival benefits in BRAFi-naïve models and in patient-derived xenograft models derived from patients who progressed to encorafenib/cetuximab therapy, supporting the activity of mosperafenib even in BRAFi-experienced patients. Additional combination studies of mosperafenib with FOLFOX resulted in tumor regression and superior activity compared with the same combination with encorafenib. Collectively, these data provide a strong preclinical rationale for the potentially transformative activity of mosperafenib as monotherapy and as a preferred backbone BRAFi for combinatorial regimen for BRAF-mutated colorectal cancer.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S2 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Quantification of immunoblotting of figure 3A,B,C
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S2 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Quantification of immunoblotting of figure 3A,B,C
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Figure S5 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Shows body weight of mice reported in fig 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure S5 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Shows body weight of mice reported in fig 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S6 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vivo efficacy of BRAFi in combination with bevacizumab in LS411N
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S6 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vivo efficacy of BRAFi in combination with bevacizumab in LS411N
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S4 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Tumor volumes of Figure 4 on a logarithmic scale
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S4 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Tumor volumes of Figure 4 on a logarithmic scale
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S9 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vitro combination of mosperafenib, binimetinib, and FOLFOX in RKO cells
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S9 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vitro combination of mosperafenib, binimetinib, and FOLFOX in RKO cells
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Suppl Table 1 shows the genetic background of PDX models
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Suppl Table 1 shows the genetic background of PDX models
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Figure S7 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Clinicopathological data from PDX models shown in figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure S7 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Clinicopathological data from PDX models shown in figure 5